Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Degludec, Both With or Without Non-insulin Anti-diabetic Drugs, in Subjects With Type 2 Diabetes Treated With Basal Insulin

X
Trial Profile

A 26-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Degludec, Both With or Without Non-insulin Anti-diabetic Drugs, in Subjects With Type 2 Diabetes Treated With Basal Insulin

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin icodec (Primary) ; Antihyperglycaemics; Insulin degludec
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ONWARDS 2
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 24 Jun 2024 According to Novo Nordisk media release, the company announced that the company has received the manufacturing and marketing approval in Japan for once-weekly Awickli Injection. The approval is based on data from ONWARDS clinical programme and approval has been approved by the Ministry of Health, Labor and Welfare for the treatment of diabetes for which insulin therapy is indicated.
    • 18 Jun 2024 According to Novo Nordisk media release, the company announced that the data of this trial will be discussed at the upcoming 84th Scientific Sessions of the American Diabetes Association (ADA). The conference will be held in-person and virtually from 21 to 24 June 2024 in Orlando, US.
    • 21 Mar 2024 According to Novo Nordisk media release, the company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Awiqli for treatment of diabetes in adults. The positive CHMP opinion is based on results from the ONWARDS phase 3a clinical trial programme. The company expects to receive final marketing authorisation from the European Commission within approximately two months.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top